Viral Infection
Conditions
Keywords
Dengue, Arbovirus Infections, Flaviviridae Infections, Flavivirus Infections, Hemorrhagic Fevers, Viral, RNA Virus Infections, Virus Diseases, Pharmaceutical Solutions, Pharmacologic Actions, Therapeutic Uses
Brief summary
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
Detailed description
This is a phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose study to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects TID for 7 days. Three cohorts of 8 subjects each (6 active, 2 placebo) are planned and up to 2 additional cohorts may be added pending safety review of the initial cohorts. Safety review will occur after each cohort. Safety is evaluated through Day 15 on the basis of adverse event (AE) monitoring, clinical laboratory testing (hematology, serum chemistry, coagulation, urinalysis), vital signs, physical examinations (PE), electrocardiograms (ECG), and fecal occult blood testing. Blood samples are collected at specified intervals up to Day 10 for pharmacokinetic assessment.
Interventions
DRUGUV-4B 30 mg oral solution
UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
DRUGUV-4B 75 mg oral solution
UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
DRUGUV-4B 150 mg oral solution
UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
DRUGUV-4B X mg (dose to be determined) oral solution
UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
DRUGUV-4B Y mg (dose to be determined) oral solution
UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
DRUGPlacebo
Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Emergent BioSolutions
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Nonsmoking, healthy male or female subject aged 18 to 45 years, inclusive. * Female subject is not pregnant and not lactating. * (Female subjects only who are not postmenopausal or sterile) agreement to use hormonal contraception OR intrauterine device PLUS barrier contraception (condom or occlusive cap such as a diaphragm or surgical vault cap) AND spermicidal foam/gel/cream/suppository starting at least 14 days before the first dose and continuing for at least 3 months after the last dose. * (Male subjects only) agreement to use barrier contraception during sexual intercourse and to also refrain from sperm donation from the first day of dosing until 3 months after the last dose of the study product. * Body weight within 60 to 90 kg, inclusive, and body mass index between 18 to 32 kg/m², inclusive. * Agreement to avoid strenuous exercise starting 4 days before the start of dosing through the period of confinement in the clinical unit and for at least 96 hours before the follow-up visits.
Exclusion criteria
* History of allergy to drugs in the iminosugar class. * Treatment with any investigational products or therapies within 30 days (or 5 half-lives, whichever is greater) before the first day of dosing. * Current or past history of disease/dysfunction of the pulmonary, cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal genitourinary, or other body system. * Abnormalities on physical examination suggestive of conditions that may pose an increased risk to the subject; abnormal electrocardiogram results (excluding benign conditions); and Grade 1 or higher abnormalities in vital signs at screening and Grade 2 or higher abnormalities in vital signs at check-in based on a modified version of the FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. * Clinical laboratory tests outside the normal range at screening and Grade 2 or higher at check-in to the clinical unit. * Creatinine clearance \< 90 mL/min (based on Cockcroft-Gault equation). * Proteinuria greater than or equal to 1+. * Any known or expected risk of bleeding. * Scheduled surgical procedure during study participation. * History of alcohol and/or drug abuse within 1 year prior to dosing and/or a positive urine drug screen for substances of abuse at screening or check-in. Urine alcohol above 50 mg/dL. * Plasma or blood donation within 30 days before the first day of dosing or intention to donate within 30 days after the final day of dosing. * Treatment with any medication, either prescription or nonprescription, including dietary supplements or herbal medications, within 14 days before dosing (within 30 days before dosing for hepatic or renal clearance-altering agents) and is unable to refrain from any medication during the study period. Exceptions are acetaminophen (not more than 2 g/day), vitamin products at recommended daily doses or hormonal birth control. * Positive serology test for HIV antibodies, hepatitis B surface antigen, or hepatitis C virus antibody at screening. * History of relevant food allergies (ie, eggs or other components of standard clinic meals) or unwilling to comply with diet restrictions. * Psychological and/or emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements; * Concurrent enrollment in any other clinical trial within 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by Group | From the time of first dosing on Day 1 through the Day 15 final follow-up visit | The incidence of TEAEs spontaneously reported by subjects or elicited during examination is reported by dose group. Subjects having multiple TEAEs are counted only once. |
| Number of Subjects Reporting Serious Adverse Events (SAEs) by Group | From the time of first dosing on Day 1 through the Day 15 final follow-up visit | The incidence of SAEs spontaneously reported by subjects or elicited during examination is reported by dose group. Subjects having multiple SAEs are counted only once. |
| Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | From the time of first dosing on Day 1 through the Day 15 final follow-up visit | Clinical laboratory abnormalities are presented as the total of Grade 1 (mild) through Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the Food and Drug Administration (FDA) Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007) and the Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Table (November 2007). Within each parameter, subjects having multiple abnormalities are counted only once. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time of Maximum Plasma Concentration (Tmax) | Day 1, Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of tmax are derived from individual subject plasma concentration-time data. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
| Area Under the Concentration-time Curve From Time Zero (Predose) to Time of the Last Quantifiable Concentration After the Last Dose [AUC(0-last)] | Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-last) are derived from individual subject plasma concentration-time data, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
| Total Daily Exposure at Steady State: Area Under the Concentration-time Curve From Time Zero (Predose) Until 24 Hours After the Last Dose [AUC(0-24)] | Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-24) are derived from individual subject plasma concentration-time data, calculated as AUC(0-8) x 3 (Day 7 last dose only). Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
| Area Under the Concentration-time Curve From Time Zero (Predose) Until 8 Hours After the Final Dose [AUC(0-8)] | Day 1, Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-8) are derived from individual subject plasma concentration-time data, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
| Number of Subjects With Outlying Vital Sign Results by Group | From the time of first dosing on Day 1 through the Day 15 final follow-up visit | Vital signs of blood pressure (BP), pulse, respiratory rate, and oral temperature were taken after being supine for 10 minutes. Orthostatic vital signs (BP, pulse) were taken after 2 minutes standing. Vital sign results are presented as the number of subjects having Grade 1 (mild) through Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the FDA Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007), or having abnormal orthostatic change (standing minus supine result). Within each parameter, subjects having multiple abnormalities are counted only once. |
| Apparent Volume of Distribution of UV-4 During the Terminal Phase (Vz/F) After Multiple Doses | Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of Vz/F are derived from individual subject plasma concentration-time data, calculated as CL/F divided by λz. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
| Apparent Terminal Half Life (t1/2) | Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of t1/2 are derived from individual subject plasma concentration-time data, calculated as ln2/λz. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
| Accumulation Ratio (AR) | Day 7 | Accumulation Ratio (AR) Day 1/Day 7 |
| Apparent Systemic Clearance (CL/F) at Steady State | Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of CL/F are derived from individual subject plasma concentration-time data, calculated as dose (free-base equivalent) divided by AUC(0-8). Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
| Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group | From the time of first dosing on Day 1 through the Day 15 final follow-up visit | ECGs (ventricular heart rate, wave intervals - PR, QRS, QT, QTcF) were recorded in a supine position (for at least 10 minutes). Baseline was calculated from the average of the triplicate ECGs on Day 1 predose. Within each parameter, subjects having multiple abnormalities are counted only once. |
| Maximum Plasma Concentration (Cmax) | Day 1, Day 7 | Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of Cmax are derived from individual subject plasma concentration-time data. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7. |
Countries
United States
Participant flow
Recruitment details
Healthy subjects were recruited from a phase 1 clinical research unit. Recruitment was initiated on 27 May 2016 and the last subject completed the final study visit for Cohort 1 on 02 March 2017.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 - 30 mg UV-4B Subjects receiving UV-4B 30 mg oral solution TID (every 8 ± 0.5 hours) for 7 days | 5 |
| Cohort 1 - Placebo Subjects receiving placebo TID (every 8 ± 0.5 hours) for 7 days | 2 |
| Total | 7 |
Baseline characteristics
| Characteristic | Cohort 1 - 30 mg UV-4B | Cohort 1 - Placebo | Total |
|---|---|---|---|
| Age, Continuous | 31.2 years STANDARD_DEVIATION 8.3 | 41.5 years STANDARD_DEVIATION 4.9 | 34.1 years STANDARD_DEVIATION 8.7 |
| Body Mass Index | 26.0 kg/m^2 STANDARD_DEVIATION 1 | 28.4 kg/m^2 STANDARD_DEVIATION 2.3 | 26.7 kg/m^2 STANDARD_DEVIATION 1.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 1 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 4 Participants | 2 Participants | 6 Participants |
| Sex: Female, Male Female | 3 Participants | 2 Participants | 5 Participants |
| Sex: Female, Male Male | 2 Participants | 0 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 2 |
| other Total, other adverse events | 5 / 5 | 2 / 2 |
| serious Total, serious adverse events | 1 / 5 | 0 / 2 |
Outcome results
Primary
Number of Subjects Reporting Serious Adverse Events (SAEs) by Group
The incidence of SAEs spontaneously reported by subjects or elicited during examination is reported by dose group. Subjects having multiple SAEs are counted only once.
Time frame: From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Population: Safety Population: all subjects who received at least one dose of study product or placebo.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 - 30 mg UV-4B | Number of Subjects Reporting Serious Adverse Events (SAEs) by Group | 1 Participants |
| Cohort 1 - Placebo | Number of Subjects Reporting Serious Adverse Events (SAEs) by Group | 0 Participants |
Primary
Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by Group
The incidence of TEAEs spontaneously reported by subjects or elicited during examination is reported by dose group. Subjects having multiple TEAEs are counted only once.
Time frame: From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Population: Safety Population: all subjects who received at least one dose of study product or placebo.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 - 30 mg UV-4B | Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by Group | 5 Participants |
| Cohort 1 - Placebo | Number of Subjects Reporting Treatment-emergent Adverse Events (TEAEs) by Group | 2 Participants |
Primary
Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group
Clinical laboratory abnormalities are presented as the total of Grade 1 (mild) through Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the Food and Drug Administration (FDA) Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007) and the Division of Microbiology and Infectious Diseases (DMID) Adult Toxicity Table (November 2007). Within each parameter, subjects having multiple abnormalities are counted only once.
Time frame: From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Population: Safety Population: all subjects who received at least one dose of study product or placebo.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | Any ≥ Grade 1 result | 5 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 activated partial thromboplastin time | 1 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 hemoglobin decreased | 5 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 leukocytes decreased | 1 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 magnesium decreased | 0 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 prothrombin time increased | 4 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 sodium decreased | 1 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 urine erythrocytes (present) | 4 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 urine erythrocytes (present) | 2 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | Any ≥ Grade 1 result | 2 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 magnesium decreased | 1 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 activated partial thromboplastin time | 0 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 sodium decreased | 0 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 hemoglobin decreased | 2 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 prothrombin time increased | 1 Participants |
| Cohort 1 - Placebo | Number of Subjects With Clinical Laboratory Abnormalities of Toxicity Grade 1 or Higher by Group | ≥ Grade 1 leukocytes decreased | 0 Participants |
Secondary
Accumulation Ratio (AR)
Accumulation Ratio (AR) Day 1/Day 7
Time frame: Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Accumulation Ratio (AR) | 1.3 Ratio | Geometric Coefficient of Variation 5.8 |
Secondary
Apparent Systemic Clearance (CL/F) at Steady State
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of CL/F are derived from individual subject plasma concentration-time data, calculated as dose (free-base equivalent) divided by AUC(0-8). Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Apparent Systemic Clearance (CL/F) at Steady State | 23.6 L/h | Geometric Coefficient of Variation 3.7 |
Secondary
Apparent Terminal Half Life (t1/2)
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of t1/2 are derived from individual subject plasma concentration-time data, calculated as ln2/λz. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 - 30 mg UV-4B | Apparent Terminal Half Life (t1/2) | 8.1 h |
Secondary
Apparent Volume of Distribution of UV-4 During the Terminal Phase (Vz/F) After Multiple Doses
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of Vz/F are derived from individual subject plasma concentration-time data, calculated as CL/F divided by λz. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Apparent Volume of Distribution of UV-4 During the Terminal Phase (Vz/F) After Multiple Doses | 246 L | Geometric Coefficient of Variation 30.6 |
Secondary
Area Under the Concentration-time Curve From Time Zero (Predose) to Time of the Last Quantifiable Concentration After the Last Dose [AUC(0-last)]
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-last) are derived from individual subject plasma concentration-time data, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Area Under the Concentration-time Curve From Time Zero (Predose) to Time of the Last Quantifiable Concentration After the Last Dose [AUC(0-last)] | 1800 ng*hr/mL | Geometric Coefficient of Variation 14.2 |
Secondary
Area Under the Concentration-time Curve From Time Zero (Predose) Until 8 Hours After the Final Dose [AUC(0-8)]
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-8) are derived from individual subject plasma concentration-time data, calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic rule for decreasing concentrations. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 1, Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Area Under the Concentration-time Curve From Time Zero (Predose) Until 8 Hours After the Final Dose [AUC(0-8)] | Day 1 AUC(0-8) | 965 ng*hr/mL | Geometric Coefficient of Variation 8.7 |
| Cohort 1 - 30 mg UV-4B | Area Under the Concentration-time Curve From Time Zero (Predose) Until 8 Hours After the Final Dose [AUC(0-8)] | Day 7 AUC(0-8) | 1270 ng*hr/mL | Geometric Coefficient of Variation 3.7 |
Secondary
Maximum Plasma Concentration (Cmax)
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of Cmax are derived from individual subject plasma concentration-time data. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 1, Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Maximum Plasma Concentration (Cmax) | Day 1 Cmax | 291 ng/mL | Geometric Coefficient of Variation 15.8 |
| Cohort 1 - 30 mg UV-4B | Maximum Plasma Concentration (Cmax) | Day 7 Cmax | 285 ng/mL | Geometric Coefficient of Variation 5.1 |
Secondary
Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group
ECGs (ventricular heart rate, wave intervals - PR, QRS, QT, QTcF) were recorded in a supine position (for at least 10 minutes). Baseline was calculated from the average of the triplicate ECGs on Day 1 predose. Within each parameter, subjects having multiple abnormalities are counted only once.
Time frame: From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Population: Safety Population: all subjects who received at least one dose of study product or placebo.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group | Any ECG abnormality | 2 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group | PR > 220 ms | 2 Participants |
| Cohort 1 - Placebo | Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group | Any ECG abnormality | 0 Participants |
| Cohort 1 - Placebo | Number of Subjects With 12-lead Electrocardiogram (ECG) Abnormalities Postdose by Group | PR > 220 ms | 0 Participants |
Secondary
Number of Subjects With Outlying Vital Sign Results by Group
Vital signs of blood pressure (BP), pulse, respiratory rate, and oral temperature were taken after being supine for 10 minutes. Orthostatic vital signs (BP, pulse) were taken after 2 minutes standing. Vital sign results are presented as the number of subjects having Grade 1 (mild) through Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the FDA Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007), or having abnormal orthostatic change (standing minus supine result). Within each parameter, subjects having multiple abnormalities are counted only once.
Time frame: From the time of first dosing on Day 1 through the Day 15 final follow-up visit
Population: Safety Population: all subjects who received at least one dose of study product or placebo.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine systolic BP ≤ 89 mmHg | 1 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 respiratory rate ≥ 17 breaths/min | 2 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine pulse ≤ 54 bpm (if baseline > 60) | 1 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | Any orthostatic change | 5 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine pulse ≤ 50 bpm (if baseline ≤ 60) | 1 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | Orthostatic change in diastolic BP ≤ -10 mmHg | 1 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine pulse ≥ 101 bpm | 0 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | Orthostatic change in pulse > 30 bpm | 5 Participants |
| Cohort 1 - 30 mg UV-4B | Number of Subjects With Outlying Vital Sign Results by Group | Any ≥ Grade 1 result | 5 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | Orthostatic change in pulse > 30 bpm | 1 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | Any ≥ Grade 1 result | 2 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine systolic BP ≤ 89 mmHg | 0 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine pulse ≤ 50 bpm (if baseline ≤ 60) | 0 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine pulse ≤ 54 bpm (if baseline > 60) | 0 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 supine pulse ≥ 101 bpm | 1 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | ≥ Grade 1 respiratory rate ≥ 17 breaths/min | 1 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | Any orthostatic change | 2 Participants |
| Cohort 1 - Placebo | Number of Subjects With Outlying Vital Sign Results by Group | Orthostatic change in diastolic BP ≤ -10 mmHg | 1 Participants |
Secondary
Time of Maximum Plasma Concentration (Tmax)
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of tmax are derived from individual subject plasma concentration-time data. Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, and 8 hrs after the first dose on Day 1; and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 1, Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Time of Maximum Plasma Concentration (Tmax) | Day 1 tmax | 0.7 h | Standard Deviation 0.2 |
| Cohort 1 - 30 mg UV-4B | Time of Maximum Plasma Concentration (Tmax) | Day 7 tmax | 1.0 h | Standard Deviation 0.4 |
Secondary
Total Daily Exposure at Steady State: Area Under the Concentration-time Curve From Time Zero (Predose) Until 24 Hours After the Last Dose [AUC(0-24)]
Plasma concentrations of UV-4 are determined by means of high performance liquid chromatography/tandem mass spectrometric assay. Values of AUC(0-24) are derived from individual subject plasma concentration-time data, calculated as AUC(0-8) x 3 (Day 7 last dose only). Blood collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 5, 6, 8, 10, 12, and 14 hrs after the final dose on Day 7.
Time frame: Day 7
Population: Pharmacokinetic Population: all subjects who received study product, had measurable values, and completed scheduled postdose pharmacokinetic measurements without protocol deviations or events thought to significantly affect the pharmacokinetics of the drug.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1 - 30 mg UV-4B | Total Daily Exposure at Steady State: Area Under the Concentration-time Curve From Time Zero (Predose) Until 24 Hours After the Last Dose [AUC(0-24)] | 3810 ng*hr/mL | Geometric Coefficient of Variation 3.7 |